aggrastat 0.25mg/ml concentrate for solution for infusion
aggrastet 0,25 mg/ml solution
pharmacare limited û woodmead - solution - see ingredients - each 1,0 ml solution contains tirofiban hydrochloride (monohydrate) equivalent to tirofiban 0,25 mg
asasantin sr
boehringer ingelheim pty ltd - dipyridamole; aspirin -
trental
clinect nz pty limited - pentoxifylline 400mg; ; - modified release tablet - 400 mg - active: pentoxifylline 400mg excipient: erythrosine hyetellose hypromellose macrogol 8000 magnesium stearate povidone purified talc purified water titanium dioxide - the treatment of peripheral occlusive vascular disease and circulatory disorders of arteriosclerotic, diabetic, inflammatory or function origin; trophic disorders (e.g., leg ulcers and gangrene).
coumadin 1 mg
taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
coumadin 2 mg
taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 2 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
coumadin 2.5 mg
taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 2.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
coumadin 5 mg
taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolis. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
asacard 162.5 mg prolonged release hard capsules
new haven pharma (uk) limited - acetylsalicylic acid - prolonged-release capsule, hard - 162.5 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid
warfant 1 mg tablets
mercury pharmaceuticals (ireland) ltd - warfarin sodium - tablet - 1 milligram(s) - vitamin k antagonists; warfarin